CURRICULUM VITAE

NAME

PRESENT POSITION

Alberto Gajofatto

since December 2013: jr. Assistant Professor in Neurology Department of Neurological and Movement Sciences University of Verona, Italy

date of birth: February 25, 1978

Consultant Neurology Unit Azienda Ospedaliera Universitaria Integrata Verona EDUCATION INSTITUTION AND LOCATION

DEGREE

YEAR

FIELD OF STUDY

Liceo Scientifico A. Messedaglia, Verona, Italy School of Medicine, University of Verona, Italy Department of Neuroscience, University of Verona, Italy Department of Neurological Science, University of Verona, Italy

B.S. M.D. Neurology Specialty Ph.D.

1997 2003 2008 2012

Sciences Medicine Neurology Neurosciences

PROFESSIONAL and RESEARCH TRAINING/PAST POSITIONS: Policlinico G.B. Rossi, University of Verona: Medical Internship: 2002 – 2003 Policlinico G.B. Rossi, University of Verona: Residency in Neurology: 2003 – 2008 UCSF Multiple Sclerosis Center, San Francisco, CA: Postdoctoral Fellowship: 2006 – 2007 Department of Neurological Sciences, University of Verona: PhD Program in Neuroscience: 2009 – 2011 Policlinico G.B. Rossi, Neurology Department, Multiple Sclerosis Center, Verona: Clinical Fellowship: 2008 – 2013

RESEARCH PROJECTS DEVISED AND MANAGED • Brain functional MRI changes in multiple sclerosis patients with spasticity; 2014 – • Correlation between cerebrospinal fluid markers of neurodegeneration and MRI measures of gray matter pathology in multiple sclerosis; 2013 –

• Natural history study of untreated benign multiple sclerosis patients; 2013 – • Clinical and cognitive evolution of multiple sclerosis with benign course: a 5-year prospective study; 2013-2014 • Natalizumab or fingolimod as second-line options for relapsing-remitting multiple sclerosis: an observational study; 2012 – 2014 • Exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS; 2009 – 2012 • Predictors of recovery, symptom recurrence, conversion to multiple sclerosis and long-term disability after acute myelitis; 2007 – 2008 • Impact of switching first-line disease-modifying therapy after treatment failure in relapsingremitting multiple sclerosis; 2006 – 2007 AWARDS AND PRIZES • Young Investigator Award for Multiple Sclerosis Research 2013; European Charcot Foundation 21st Annual Meeting; Baveno, 28-30 November 2013 • Neuroimmunology and Demyelinating Diseases Special Interest Group; American Neurological Association 134th Annual Meeting; Baltimore, 11-14 October 2009 COLLABORATIONS • Istituto Superiore di Sanità: molecular markers of cortical pathology in multiple sclerosis; 2013 – • RiReMS group: rising researchers in multiple sclerosis; 2013 – • Regione Veneto: surveillance of flaccid paralysis cases in Veneto region; 2012 – 2013 • UCSF, University of California San Francisco: response predictors and switching strategies of disease-modifying therapies for multiple sclerosis; 2006 – 2010

PARTICIPATION IN MULTICENTER STUDIES AND CLINICAL TRIALS • Beta-interferon in Early relapsing-remitting multiple sclerosis Surveillance Trial (Mult Scler

2007; 13: S49) • GERONIMUS Study (Gruppo Emiliano-ROmagnolo Neurologi In MUltiple Sclerosis) (Eur J

Neurol 2009; 16, Suppl 3: 245) • MAIN trial (Neuroepidemiology 2009; 33: 197) • CFTY720D2316: A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis.

• BD0109: Relationship between IL-6 and TNF-α polymorphism with flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1 a im • CFTY720D2399: A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis • NGM114840: A randomized, single blind, placebo-controlled, single ascending dose/repeat dose cohort study to assess safety, tolerability, pharmacokinetics and immunogenicity of GSK1223249 in patients with relapsing forms of multiple sclerosis • CFTY720DIT03: An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists • EFC6058 – Teracles: A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta

TEACHING - Demyelinating diseases; Residency Program in Neurology, University of Verona; 2015 – - Neurology; Nursing School, University of Verona, 2015 – - Neurological examination; School of Medicine, University of Verona, 2014 –

MENTORING OF STUDENTS AND RESIDENTS -

Mattia Zanoni, medical student; Medical Degree thesis: “Correlation between cerebrospinal fluid markers of neurodegeneration and MRI measures of gray matter pathology in multiple sclerosis”; 2014

-

Maria Rachele Bianchi, resident in Neurology; final dissertation: “Clinical and cognitive evolution of multiple sclerosis with benign course: a 5-year prospective study”; 2014

-

Ambra Stefani, medical student; Medical Degree thesis: “Prevalence of multiple sclerosis in Verona, Italy”; 2010

PEER REVIEW

Neurology, Journal of Neurology Neurosurgery and Psychiatry, European Journal of Neurology, BMC Neurology, Clinical Neurology and Neurosurgery, European Journal of Physical and Rehabilitation Medicine

PUBLICATIONS: Articles in peer-reviewed journals 1.

Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line diseasemodifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009; 15:50-58 (IF: 3.279; JCR 2009)

2.

Gajofatto A, Monaco S, Fiorini M, Zanusso G, Vedovello M, Rossi F, Turatti M, Benedetti MD. Assessment of outcome predictors in first-ever acute myelitis: a retrospective study on 53 cases. Arch Neurol 2010; 67:724-730 (IF: 6.312; JCR 2009)

3.

Turatti M, Gajofatto A, Rossi F, Vedovello M, Benedetti MD. Long survival and clinical stability in Marburg’s variant multiple sclerosis. Neurol Sci 2010; 31:807-811 (IF: 1.220; JCR 2010)

4.

Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree B, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. Plos One 2011; 6(2):e16664 (IF: 4.092, JCR 2011)

5.

Invernizzi P, Bertolasi L, Turatti M, Bianchi MR, Gajofatto A, Benedetti MD. Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. J Neurol. 2011; 258:1933-1939 (IF: 3.473, JCR 2011)

6.

Zanusso G, Fiorini M, Ferrari S, Gajofatto A, Cagnin A, Galassi A, Richelli S, Monaco S. Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. Int J Mol Sci. 2011;12(9):6281-92 (IF: 2.598, JCR 2011)

7.

Gajofatto A, Bongianni M, Zanusso G, Benedetti MD, Monaco S. Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? Int J Mol Sci 2011; 12(11):7960-70 (IF: 2.598, JCR 2011)

8.

Bertolasi L, Acler M, Dall'ora E, Gajofatto A, Frasson E, Tocco P, Turri M, Ferlisi M, Fiorini M, Pimazzoni F, Squintani G, Martini M, Danzi B, Monaco S. Risk factors for post-polio syndrome among an Italian population: a case-control study. Neurol Sci. 2012; 33(6):1271-5 (IF: 1.412, JCR 2012)

9.

Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-Related Nervous System Disorders. Clin Dev Immunol. 2012; 2012:236148. Epub 2012 Jul 30 (IF: 3.064, JCR 2012)

10. Gajofatto A, Benedetti MD. Prognostic factors of acute partial transverse myelitis. Arch Neurol. 2012; 69:1523 (IF: 7.584; JCR 2011) 11. Turatti M, Gajofatto A, Bianchi MR, Ferrari S, Monaco S, Benedetti MD. Benign course of tumour-like multiple sclerosis: report of five cases and literature review. J Neurol Sci.

2013; 324(1-2):156-62 (IF: 2.243; JCR 2012) 12. Gajofatto A, Stefani A, Turatti M, Bianchi MR, Gomez Lira M, Moretto G, Salviati A, Benedetti MD. Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study. Eur J Neurol. 2013; 20(4):697-703 (IF: 4.162; JCR 2012) 13. Bertolasi L, Frasson E, Turri M, Gajofatto A, Bordignon M, Zanolin E, Martini M, Pimazzoni F, Ferlisi M, Zanusso G, Rossi M, Monaco S. A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome. J Neurol Sci. 2013; 330(1-2):94-9 (IF: 2.243; JCR 2012) 14. Gajofatto A, Bongianni M, Zanusso G, Bianchi MR, Turatti M, Benedetti MD, Monaco S. Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. Acta Neurol Scand. 2013; 128:336-344 (IF: 2.474; JCR 2012) 15. Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers 2013;35(6):687-99 (IF: 2.140; JCR 2012) 16. Gajofatto A, Bianchi MR, Deotto L, Benedetti MD. Are Natalizumab and Fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. Eur Neurol. 2014;72:173-180 (IF: 1.362; JCR 2013) 17. Gajofatto A, Gobbin F, Piffer S, Calabria F, Forlivesi S, Fenzi F, Barbieri A, Lunardi C, Monaco S, Benedetti MD. Two Sisters with Leukoencephalopathy, Hearing Loss and Retinopathy: A Familial Case of Susac's Syndrome? Br J Med Med Res 2014; 4(36):5818-5824 18. Calabrese M, Gajofatto A, Benedetti MD. Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy. Expert Rev Neurother. 2014;14(12):1417-28. (IF: 2.834; JCR 2013) 19. Calabrese M, Gajofatto A, Gobbin F, Sala F, Turri G, Richelli S, Matinella A, Oliboni ES, Benedetti MD, Monaco S. Late-onset multiple sclerosis presenting with cognitive dysfunction and cortical/infratentorial atrophy. Mult Scler. 2015;21(5):580-89 (IF: 4.863; JCR 2013) 20. Gandolfi M, Munari D, Geroin C, Gajofatto A, Benedetti MD, Midiri A, Carla F, Picelli A, Waldner A, Smania N. Sensory integration balance training in patients with multiple sclerosis: a randomized, controlled trial. Mult Scler. 2015 Jan 12 [Epub ahead of print] (IF: 4.863; JCR 2013) 21. Matinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S, Monaco S, Ferrari S. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. J Neurol. 2015;262(5):1317-27 (IF: 3.841; JCR 2013) 22. Mattarozzi K, Casini F, Baldini M, Baldin E, Lugaresi A, Milani P, Pietrolongo E, Gajofatto A, Leone M, Riise T, Vignatelli L, D’Alessandro R, on behalf of G.E.Ro.N.I.Mu.S. group. Assessing

subjective quality of life domains after multiple sclerosis diagnosis disclosure. Health

Expect. 2015 Apr 24 [Epub ahead of print] (IF: 2.852; JCR 2013) 23. Gajofatto A, Turatti M, Bianchi MR, Forlivesi S, Gobbin F, Azzarà A, Monaco S, Benedetti MD. Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions. Acta Neurol Scand. 2015 May 26 [Epub ahead of print] (IF: 2.474; JCR 2012) 24. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases 2015 Jul 16 [Epub ahead of print] 25. Calabrese M, Reynolds R, R. Magliozzi R, Castellaro M, Morra M, Scalfari A, Farina G, Romualdi C, Gajofatto A, Benedetti MD, Monaco S. Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients. Plos One; accepted (IF: 3.234, JCR 2014) 26. Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A, Monaco S. Brentuximab vedotin: axonal microtubule's Apollyon. Blood Cancer J; accepted (IF: 3.467, JCR 2014)

Abstracts Gomez-Lira M, Ottaviani S, Mazzola S, Salviati A, Gajofatto A, Turri E, Fiumani A, Deotto L, Moretto G, Rizzuto N, Benedetti MD. A Case-control study of myelin oligodendrocyte glycoprotein and CD45 polymorphisms in multiple sclerosis in Verona, Italy. Annals of Neurology 2004; 56(suppl8):S31-32 Turri E, Ottaviani S, Rasia S, Gajofatto A, Moretto G, Rizzuto N, Benedetti MD. Prognostic indicators of “benign” clinical course in multiple sclerosis patients. Neurological Sciences 2004; 25(suppl):s151-s152 Turatti M, Rasia S, Turri E, Gajofatto A, Zanusso G, Monaco S, Rizzuto N, Benedetti MD. Tumorlike multiple sclerosis: three cases misdiagnosed as primary brain neoplasm. Neurological Sciences 2005; 26(suppl):s267 Rossi F, Invernizzi P, Rasia S, Turri E, Turatti M, Gajofatto A, Bonetti B, Rizzuto N, Benedetti MD. A case of multifocal CIS with unusual MRI features suggestive of Balo’s concentric sclerosis. Neurological Sciences 2006; 27(suppl):s190 Gajofatto A, High A, Waubant E. Impact of switching first-line disease-modifying therapy after treatment failure in relapsing-remitting multiple sclerosis. Annals of Neurology 2007; 62(suppl11):S69-70 Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Demographic and clinical predictors of response to interferon beta and glatiramer acetate as first-line treatment for relapsing-remitting multiple sclerosis. Multiple Sclerosis 2007; 13(suppl2):S57-58

Mowry E, Gajofatto A, Blasco MR, Castillo-Trivino T, Chabas D, Waubant E. Long lesions on initial spinal cord MRI predict a final diagnosis of acute disseminated encephalomyelitis versus multiple sclerosis in children. Neurology 2008; 70(suppl1) Gajofatto A, Monaco S, Fiorini M, Zanusso G, Vedovello M, Rossi F, Turatti M, Benedetti MD. Increased cerebrospinal fluid cystatin C may predict disability after acute myelitis. Annals of Neurology 2009; 66 (suppl13):s36 Vedovello M, Invernizzi P, Rossi F, Turatti M, Gajofatto A, Toniolo M, Vassanelli C, Morando G, Benedetti MD. Acute cardiovascular dysfunction in multiple sclerosis: report of two cases and literature review. Neuroepidemiology 2009; 33:198 Gajofatto A, Fiorini M, Monaco S, Turatti M, Bianchi MR, Fiaschi A, Benedetti MD. Predicting the natural course of clinically isolated syndromes: an exploratory study of cerebrospinal fluid biomarkers. Multiple Sclerosis 2010; 16(suppl10):S347 Castillo-Trivino T, Gajofatto A, Waubant E. Clinical and demographic predictors of response to first-line therapies in relapsing-remitting multiple sclerosis. Neurology 2011; 76 (suppl4) Bianchi MR, Gajofatto A, Turatti M, Richelli S, Fiaschi A, Benedetti MD. An active case of radiologically isolated syndrome: from MRI detection to multiple sclerosis. Neurological Sciences 2011; 32 (suppl): s100-s101 (42° Congresso della Società Italiana di Neurologia, Torino) Gajofatto A, Bongianni M, Fiorini M, Zanusso G, Bianchi MR, Richelli S, Turatti M, Benedetti MD, Monaco S. A panel of exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS: does it add relevant information to usual work-up? Neurology 2012; 78 (suppl) Zanusso G, Fiorini M, Gajofatto A, Monaco S. Physicochemical properties of Aβ peptides in cerebrospinal fluid of Alzheimer’s disease patients. Journal of Alzheimer’s disease 2012; 29 (suppl.1):99 Turri M, Bertolasi L, Frasson E, Acler M, Ferlisi M, Pimazzoni, Gajofatto A, Didonè G, Bordignon M, Vicentini S, Dall'ora E, Brigo F, Fiaschi A, Martini M, Danzi B, Monaco S. Intravenous immunoglobulin for post-polio syndrome: a randomized double-blind, placebocontrolled study. European Journal of Neurology 2012; 19 (suppl.1):275 Gajofatto A, Stefani A, Turatti M, Bianchi MR, Gomez Lira M, Salviati A, Benedetti MD. Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study. Multiple Sclerosis Journal 2012; 18 (suppl.4):313-314 Gajofatto A, Bianchi MR, Benedetti MD. Natalizumab or fingolimod for relapsing-remitting multiple sclerosis: a prospective study. Neurological Sciences 2013; 34 (suppl): s314-315 Gobbin F, Gajofatto A, Piffer S. Fenzi F, Benedetti MD, Monaco S. Two sisters with

leukoencephalopathy, hearing loss and retinopathy: a familial case of Susac's syndrome? Neurological Sciences 34 (suppl): s337-338 Calabrese M, Gobbin F, Turri G, Richelli S, Matinella A, Gajofatto A, Benedetti MD, Monaco S. Cognitive onset in multiple sclerosis. Neurological Sciences 2013; 34 (suppl): s392 Gajofatto A, Bianchi MR, Turatti M, Forlivesi S, Gobbin F, Monaco S, Benedetti MD. Physical disability and cognitive impairment evolution in benign multiple sclerosis: a five years prospective study. Mult Scler 2014; 20 (Suppl) Calabrese M, Reynolds R, Magliozzi R, Castellaro M, Scalfari A, Howell OW, Morra M, Farina G, Romualdi C, Gajofatto A, Benedetti MD, Monaco S. Regional distribution and evolution of grey matter changes in different MS phenotypes: a 5-year longitudinal study. Mult Scler 2014; 20 (Suppl) Calabrese M, Gasperini C, Tortorella C, Malucchi S, Ragonese P, De Luca G, Fantozzi R, Lo Fermo S, Boffa L, Paolicelli D, Gajofatto A, Pesci I, Annovazzi P, Cordioli C, Lanzillo R, Giorgio A, Gallo A, Tomassini V, Frisullo G, Prosperini L, Cocco E, Rodegher M, Solaro C. The diagnosis of multiple sclerosis: pinpointing the concept of "no better explanation". Mult Scler 2014; 20 (Suppl) Gajofatto A, Bongianni M, Zanoni M, Forlivesi S, Calabrese M, Turatti M, Monaco S, Benedetti MD. Correlation between cerebrospinal fluid markers of neurodegeneration and MRI measures of gray matter pathology in multiple sclerosis. Neurol Sci 2014; Suppl Forlivesi S, Gajofatto A, Bianchi MR, Calabrese M, Milano E, Sgaramella TM, Monaco S, Benedetti MD. Long-term clinical, cognitive and MRI characteristics of patients with untreated benign multiple sclerosis: a natural history study. Neurol Sci 2014; Suppl CITATION OVERVIEW (source: Scopus, accessed on August 4th, 2015) Total number of citations: 174 H-index: 7 August 4th, 2015